Brasília – Anvisa is fast-tracking the review of 20 weight-loss injection pens after receiving a formal request from the Ministry of Health. The products, based on liraglutide and semaglutide, are under evaluation from companies such as EMS, Megalabs, and Momenta. According to the agency, part of the analyses will be completed later this year, while additional dossiers are scheduled for 2026 and 2027 to expand domestic availability.
Special Report – Anvisa
Get access to the report about Anvisa’s exceptional measures to speed up drug registration in Brazil. Click below to purchase the 12-page PDF. Secure payment via Stripe.
The initiative aligns with the government’s strategy to increase national production capacity for GLP-1–based therapies amid rising demand and supply constraints in Brazil. The Ministry of Health argues that expanding the number of authorized products may reduce dependency on imports and stabilize the market.
Source: Valor Econômico
Need to understand Brazil’s market and political landscape?
Contact Pietro Rubin — pharmabrnews@gmail.com
Leave a Reply